Trial Profile
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Telaglenastat (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Refractory anaemia
- Focus Adverse reactions; Therapeutic Use
- 17 Mar 2023 Status changed from active, no longer recruiting to completed.
- 22 Sep 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2023.
- 25 Feb 2022 Status changed from recruiting to active, no longer recruiting.